INTRODUCTION AND OBJECTIVES: Disease severity may modulate the effects of prostate cancer treatment on patient-reported functional outcomes. The objective of this study is to determine how the effects of contemporary prostate cancer treatments on functional outcomes vary by disease risk.
METHODS: The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study is a prospective, populationbased, observational study which enrolled men with localized prostate cancer in 2011 and 2012. Patient-reported function was measured using the 26-item Expanded Prostate Index Composite (EPIC) at baseline, 6, 12, and 36 months after treatment. To identify differences in the effect of treatment on EPIC domain scores by disease risk, we fit a set of longitudinal models with interactions between disease risk and treatment type (radical prostatectomy [RP] or external beam radiotherapy [EBRT] ) with adjustments for the following factors: time since treatment, pre-treatment function, age, race, comorbidity, educational attainment, insurance type, employment, marital status, physical function score, social support, depression score, participatory decisionmaking score, and study site.
RESULTS: Among the 2544 participants, 1144 (45%) had low-risk, 983 (39%) had intermediate-risk, and 417 (16%) had highrisk disease. Among low-risk patients, RP causes more severe decreases in sexual function compared to EBRT at 3 years (mean difference in EPIC score: -14.30 [95% CI: -18.56, -10.53]); however, among high-risk patients, this difference becomes both clinically and statistically insignificant (-4.46 [-9.79, 0.88] ). With respect to incontinence, RP leads to even greater declines in function among high-risk patients compared to EBRT at 3 years (difference in treatment effects among low risk: -14.60 [-18.00, -11.19 ] and high risk: -19.25 [-23.87, -14.62]) . No clinically significant interactions between treatment and risk were detected among the bowel, hormone, or urinary irritative domains.
CONCLUSIONS: These data suggest that the effect of treatment on urinary incontinence and sexual function vary by disease risk. Namely, high-risk patients report similar sexual function at 3 years regardless of treatment type but more drastic declines in urinary incontinence after surgery. INTRODUCTION AND OBJECTIVES: Diabetes has been associated with lowered overall risk of prostate cancer (PCa), yet the risk of high-grade tumors may be elevated. The role of hyperglycemia as PCa risk factor is unclear. We estimated PCa risk overall and by tumor grade and stage among men with diabetic fasting blood glucose level in a population-based cohort of Finnish men.
METHODS: The study population of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) was linked to the Fimlab laboratory database to obtain information on fasting plasma/ blood glucose measurements since 1978. The data was available for 17,860 men. Based on the average yearly glucose level men were categorized as normoglycemic, prediabetic or diabetic for each followup year separately. Follow-up started at the FinRSPC baseline in 1996-1999 and continued until prostate cancer diagnosis, death, or the end of 2014. Cox regression with adjustment for age, FinRSPC study arm and use of statins, antihypertensive drugs, NSAIDs, aspirin, 5a-reductase inhibitors and alpha-blockers was used to calculate hazard ratios (HRs) and 95% confidence intervals (95%CIs) for prostate cancer overall and separately for Gleason 6, Gleason 7-10, localized and metastatic tumors.
RESULTS: During the median follow-up of 14.7 years a total of 1,663 new PCa cases were diagnosed. Compared to normoglycemic men, men with diabetic blood glucose level had increased risk of PCa (HR 1.52; 95% CI 1.31-1.75). The risk increase was observed for all tumor grades, but the risk of being diagnosed with metastatic PCa was not elevated. The risk increase was observed if the blood glucose level was diabetic in the 1990s (HR 1.39; 95% CI 1.16-1.67 (CaP) is associated with an increased risk of CaP. However, it remains unclear how this association impacts the need for screening. The aim of this study is to evaluate the impact of FH of the diagnosis of clinically significant CaP in a large national cohort.
METHODS: The study included 73,045 men from the control and screening arms of the Prostate Lung Colorectal and Ovarian (PLCO) trial, which had complete information regarding FH and CaP diagnosis. Incidence of clinically significant cancer (CS; intermediate or high risk disease) was compared by FH. The relationship between number of relatives diagnosed and age at CaP diagnosis was evaluated. Multivariable logistic regression was used to estimate odds rato (OR) and 95% confidence intervals (CI).
RESULTS: FH was associated with a significantly increased risk of both CaP [OR 1.6, (95% CI 1.5-1.8)] and CS-CaP [OR 1.7 (95% CI 1.5-1.8), respectively]. Furthermore, the impact of FH on CS-CaP increased with the number of family members with CaP; for participants with one relative, the OR was 1.6 (95% CI 1.5-1.8); for those with multiple relatives, the OR increased to 2.2 (95% CI 1.6-3.2). Men with younger relatives with prostate cancer (< 65 vs 65 years) were more likely to be diagnosed with CS-CaP, [OR 1.6, (95%CI 1.3-2.0)]. FH, number of affected relatives and age of relatives remained significant on multivariable analysis controlling for ages, race, smoking history, history of BPH, marital status employment status and study arm.
CONCLUSIONS: Detailed FH, including the number of relatives and relatives 0 age of at diagnosis significantly affect a man 0 s risk of CS-CaP and should be taken into consideration during individualized counseling about the frequency and intensity of screening. completely understood. In addition to cholesterol-lowering, statins also have systemic anti-inflammatory properties, but the effect of serum cholesterol levels and statin use on benign prostate inflammation has not been explored. The aim of this study was to examine associations between serum lipid levels, statin use, and histological prostate inflammation among men with a negative prostate biopsy.
METHODS: We conducted a retrospective analysis of data from 6,655 men with a negative baseline prostate biopsy in the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Statin use and serum lipid levels [total cholesterol, low and high density lipoprotein (LDL and HDL, respectively), triglycerides] were assessed at baseline. Prostate inflammation was classified as chronic (lymphocytes, macrophages) or acute (neutrophils) following central histological review of negative baseline prostate biopsies. Multinomial logistic regression was used to examine the effect of serum lipid levels and statin use on presence and extent of chronic and acute prostate inflammation [none, moderate (<20% biopsy cores), severe (20% biopsy cores)], adjusting for potential confounders.
RESULTS: Chronic and acute prostate inflammation was found in 5,152 (77%) and 1,005 (15%) men, respectively. Serum lipid levels were not associated with presence or extent of chronic prostate inflammation. Total cholesterol, LDL and triglycerides were not associated with presence or extent of acute prostate inflammation. However, men with high HDL (60 vs. <40 mg/dl) had reduced presence of any acute inflammation (OR 0.79; 95% CI 0.63-0.99), and were less likely to have severe acute inflammation (OR 0.66; 95% CI 0.45-0.97). Statin users had reduced presence of any chronic prostate inflammation (OR 0.81; 95% CI 0.69-0.95), and were less likely to have severe chronic inflammation and severe acute inflammation (OR 0.80; 95% CI 0.68-0.95 and OR 0.73; 95% CI 0.53-1.00, respectively), relative to non-users.
CONCLUSIONS: In a cohort of men with a negative prostate biopsy, those with high HDL had lower presence and extent of acute prostate inflammation and statin users had reduced presence and extent of chronic inflammation. These findings support an effect of HDL and statin use on benign prostate inflammation. As we have shown inflammation is correlated with prostate cancer risk, this work suggests a mechanism linking serum lipid levels, statins and prostate cancer risk. INTRODUCTION AND OBJECTIVES: Annually over 10,000 men are diagnosed with prostate cancer (PC) in the Netherlands and almost half are older than 70 years. As the effect of treatment might differ for older patients, we examined the clinical features, applied treatments, and prognosis for older PC patients in the Netherlands.
Source of
METHODS: All patients diagnosed with PC in 2013 were retrieved from the database of the nationwide population-based Netherlands Cancer Registry. We examined the clinical characteristics, treatment, and 5-year relative survival (as approximation of PC specific survival) of patients aged 0-60, 60-69, 70-79, and 80.
RESULTS: Approximately 46% (n¼5001) of diagnosed PC patients in 2013 were 70 years and 10% (n¼1164) 80 years. PSA level at diagnosis and Gleason score progressively increased with age. Also, older patients were more often diagnosed with advanced stage of PC (cT4/N+/M+) compared to younger patients; 12% of patients aged <60 years versus 39% of patients aged 80 years had an advanced stage. For all disease stages combined, the proportion of patients that underwent curative treatment decreased with increasing age. Within the group of cT2 patients, 70% of patients aged 70-79 years and 16% of patients aged 80 years were treated with curative intent compared to
